| Tumour group / site | Trial title | Date opened
|
|---|
BREAST
| Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
BCCA CODE: BRTCLIMB
| 6 Sep 2018
|
| A phase IIIb, single-arm, open-label multicentre study of olaparib monotherapy in the treatment of HER2-ve metastatic breast cancer patients with germline BRCA1/2 mutations
BCCA CODE: BRTLUCY
| 18 May 2018
|
| A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin As Adjuvant Therapy For HER2 Negative Breast Cancer: The ABC Trial
BCCA CODE: BRMAC21
| 9 May 2018
|
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR–POSITIVE, HER2-NEGATIVE BREAST CANCER
BCCA CODE: BRTIPATUNI
| 01 May 2018
|
| A phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, horone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment
BCCA CODE: BRTBYLIEVE
| March 2018
|
| A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
BCCA CODE: BRMA37
| September 2017
|
| A study evaluating the pregnancy outcomes and safety of interupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (positive)
BCCA CODE: BRMAC18
| July 2017
|
| An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
BCCA CODE: BRTCOMPLEE | July 2017
|
| A randomized, multicenter, double-blind, placebo-controlled phase II study of the efficacy and safety of trastuzumab emtansine in combination with atezolizumab-placebo in patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab and taxane based therapy
BCCA CODE: BRTKATE2 | November 2016 |
| Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy
BCCA CODE: BRTYCA09 | November 2016 |
| A randomised, double-blind, parallel group, placebo-controlled multi-centre phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
BCCA CODE: BRMA36
| February 2016 |
| A phase III, multicenter, randomized, placebo-controlled study of MPDL3280A(Anti-PD-L1 Antibody) in combination with Nab-Pacilitaxel compared with placebo with Nab-Paclitaxel for patients with previously untreated metastatic triple-negative breast cancer
BCCA CODE: BRT29522
| January 2016 |
| A phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy
BCCA CODE: BRTPENELOP
| November 2015 |
| A phase III, double blind, placebo-controlled, randomized study of Taselisib plus Fulvestrant versus placebo plus Fulvestrant in postmenopausal women with estrogen receptor-positive and HER2 negative locally advanced or metastatic breast cancer who have disease recurrence or progression during or after aromatase inhibitor therapy
BCCA CODE: BRTPIPER
| July 2015 |
CENTRAL NERVOUS
SYSTEM (CNS) | A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma (CheckMate 548: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 548)
BCCA CODE: CNT209548 | January 2017 |
GASTROINTESTINAL (GI)
| Neoadjuvant
chemotherapy, Excision and Observation for early rectal cancer (CCTG) BCCA CODE: GICO28
| 21 Jun 2018
|
| A PHASE III, RANDOMISED, INTERNATIONAL TRIAL COMPARING mFOLFIRINOX TRIPLET CHEMOTHERAPY TO mFOLFOX FOR HIGH RISK STAGE III COLON CANCER IN ADJUVANT SETTING (IROCAS STUDY)
BCCA CODE: GICO27
| April 2018
|
| COMPHREHENSIVE GENOMIC PROFILING OF COLORECTAL CANCER PATIENTS WITH ISOLATED LIVER METASTASES TO UNDERSTAND RESPONSE & RESISTANCE TO CANCER THERPAY
BCCA CODE: GICOMPARIS
| April 2018
|
| Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma subtypes by comprehensive Genomic Analysis
BCCA CODE: GITPANGEN | February 2017
|
| A phase II randomized study of durvalumab and tremelimumab and best supportive care vs. best supportive care alone in patients with advanced colorectal adenocarcinoma refractory to standard therapies
BCCA CODE: GICO26 | January 2017 |
| A randomized multicenter double blind phase III study of nivolumab or placebo in subjects with resected lower esophageal or gastroesophageal junction cancer
BCCA CODE: GIT209577
| September 2016 |
| A phase II/III of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision.
BCCA CODE: GICRC7
| August 2013
|
| | A phase lll study of the impact of a physical activity program on disease-free survival in patients with high risk stage ll or stage lll colon cancer: a randomized controlled trial (challenge) BCCA CODE: GICO21
| July 2009
|
GENITOURINARY (GU) - BLADDER
| An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (GUTBISCAY)
BCCA CODE: GUTBISCAY
| October 2017
|
| A phase III, open-label, multicenter, randomized study of atezolizumab (anti-PD-L1 antibody) versus observation as adjuvant therapy in patients with PD-L1-selected, high risk muscle-invasive bladder cancer after cystectomy
BCCA CODE: GUT29636 | March 2016 |
GENITOURINARY (GU) - Kidney
| A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse BCCA CODE: GUT914 |
22 Aug 2018
|
| A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR)
BCCA CODE: GUTCLEAR | 5 Jul 2018 |
| A multi-center, open label, randomized phase II study of AGS-16C3F vs axitinib in metastatic renal cell carcinoma
BCCA CODE: GUT16C3F
| April 2016
|
| A phase II, multi-centre study, of stereotactic radiotherapy for oligo-progression in metastatic renal cell cancer patients receiving 1st line sunitinib therapy
BCCA CODE: GUTSUNI | December 2015 |
| GENITOURINARY (GU) - Testis | Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma with Isolated Retroperitoneal Disease (1-3cm)
BCCA CODE: GUSEMS | 11 Sep 2018
|
| GENITOURINARY (GU) - Prostate
| A
Phase II Study of Palbociclib, a CDK4/6 Inhibitor, In Patients With Metastatic
Castration-Resistant Prostate
BCCA CODE: GUIND223
| 22 Aug 2018
|
| Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study
BCCA CODE: GUIND234
| 22 Aug 2018
|
| A Multicentre Cohort Study of Patients with Advanced Prostate Cancer in Canada
BCCA CODE: GURC
| 3 Jul 2018
|
| An International Registry for Men with Advanced Prostate Cancer
BCCA CODE: IRONMAN
| April 2018
|
| A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
BCCA CODE: GUTCR2001
| December 2017
|
| A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
BCCA CODE: GUT39303
| December 2017
|
| A Phase III, Randomized, Open Label, Randomized Study To Assess the Efficacy and Safety of Olaparib (LynparzaTM) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations
BCCA CODE: GUTPROFOUN
| November 2017
|
| A Safety and Pharmacokinetics Study of Niraparib plus Androgen Receptor-Targeted Therapy (Apalutamide or Abiraterone Acetate plus Prednisone) in Men with Metastatic Castration-Resistant Prostate Cancer BCCA CODE: GUTBEDIVER
| June 2017
|
| A phase II study of durvalumab (MEDI4736) with or without tremelimumab in patients with castration resistant prostate cancer
BCCA CODE: GUIND232 | January 2017 |
| A phase I/II open-label study to assess the safety, pharmcokinetics, and anti-tumor activity of oral EPI-506 in patients with metastatic castration-resistant prostate cancer
BCCA CODE: GUTCS0001
(on HOLD as of January 9, 2015) | December 2015 |
GYNECOLOGY
| Phase I (Safety Assessment) of Durvalumab (MEDI4736) with Focal Sensitizing Radiotherapy in Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Epithelial Carcinoma
BCCA CODE: GOTABSRT
| 28 May 2018
|
| A Retrospective/
Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours BCCA CODE:
GOTOZM061
| August 2017
|
| A phase 3 randomized, double-blind, placebo-controlled multicentre study of Niraparib maintenance treatment in patients with HRD-positive advanced ovarian cancer following response to front-line platinum-based chemotherapy
BCCA CODE: GOTPRIMA | February 2017 |
| HEAD & NECK | A two-arm, open-label, randomized phase II study of Pembrolizumab (MK3475) monotherapy versus standard chemotherapy in platinum pre-treated, recurrent or metastatic nasopharyngeal cancer
BCCA CODE: HNT3475122
| June 2016 |
LUNG
| A Phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients withtreatment-naïve advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy
BCCA CODE: LUT29872
| December 2017
|
| Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab +/- Platinum-based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer
BCCA CODE: LUBR34
| October 2017
|
| A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer
BCCA CODE: LUBR31
| July 2015 |
| A randomized phase II trial of selumetinib in patients receiving standard pemetrexed and cisplatin chemotherapy for the treatment of advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer
BCCA CODE: LUIND219
(on HOLD as of June 10, 2015) | June 2015 |
LYMPHOMA
| A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide,
Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation
in Patients with CD30-Positive Peripheral T-cell Lymphoma BCCA CODE: LYTCHEPBV | 9 Sep 2018
|
| Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects with Mantle Cell Lymphoma Pharmacyclics PCYC-1143-CA BCCA CODE: LYTPCYC (Part 2 opened 3Aug2018) | 18 Jul2018
|
| A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies
BCCA CODE: LYT224022 | 24 May 2018 |
| A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
BCCA CODE: LYT209647 | July 2017
|
| A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic malignancies
BCCA CODE: LYTTT1621 | May 2017
|
| An open-label, multicenter, phase I trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A in patients with relapsed or refractory B-cell non-hodgkin's lymphoma and chronic lymphocytic leukemia (CLL)
BCCA CODE: LYT29781
| February 2016 |
| A phase I/II study to evaluate the safety and preliminary efficacy of nivolumab in combination with brentuximab vedotin in subjects with relapsed refractory non-hodgkin lymphomas with CD30 expression CheckMate 436: CHECKpoint pathway and nivolumab clinical trial evaluation
BCCA CODE: LYT209436
| December 2015 |
| A multi-staged randomized phase II study of novel combination therapy in the treatment of relapsed and refractory aggressive B-cell lymphoma
BCCA CODE: LYLY17
| September
2015 |
| A phase IB/II, open-label study evaluting the safety and pharmacokenetics of GDC-0199 (ABT-199) in combination with rituximab(R) or obinutuzumab(G) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with B-cell non-hodgkin's lymphoma (NHL) and DLBCL
BCCA CODE: LYT27878 | February 2015 |
PHASE 1
| A Phase 1/2, Open Label, Multicenter Study of the Combination of NKTR-214, and Nivolumab, or the Combination of NKTR-214, Nivolumab and ipilimumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
BCCA CODE: P1TPIVOT02
| June 2018
|
| A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
BCCA CODE: P1PJC021
| April 2018
|
| CANADIAN PROFILING AND TARGETED AGENT UTILIZATION TRIAL (CAPTUR) A PHASE II BASKET TRIAL
BCCA CODE: P1PM1
| March 2018
|
| A phase-Ib dose-finding study of the SMAC mimetic Debio 1143 when given in combination with the anti-PD-L1 antibody avelumab to patients with advanced solid malignancies and, in an expansion cohort, to patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)
BCCA CODE: P1T1143
| March 2018
|
| A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
BCCA CODE: P1PJC021
| January 2018
|
| A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
BCCA CODE: P1TGARNET
| September 2017
|
| A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors
BCCA CODE: P1TLEETMT
| September 2017
|
| A Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in patients with Advanced Solid Tumors | September 2017 |
| A Phase I trial of MLN0128 (Tak-228) in combination with osimertinib (AZD9291) in advanced EGFR mutation positive non-small cell lung cancer (NSCLC) after progression on a previous EGFR tyrosine kinase inhibitor. BCCA CODE: P1PJC020 | September 2017 |
| A Phase II Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
BCCA CODE: P1PJC022
| August 2017
|
| An open-label, dose escalation, safety, and pharmacokinetic study of CFI-402257 administered orally to patients with advanced solid tumours
BCCA CODE: P1T402257 | May 2017 |
| A phase II study of durvalumab (MEDI4736) and tremelimumab in patients with advanced rare tumours
BCCA CODE: MOIND228 | April 2017 |
| A phase I/Ib, open-label, multi-center, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with selected incurable cancers
BCCA CODE: P1TCPI444
| February 2017 |
| A phase I/II study of CX5461
BCCA CODE: P1IND231
| September 2016 |
| A phase I/IIa study of BMS-986205 in combination with nivolumab (BMS-986558, anti PD-1 Monoclonal Antibody) in advanced malignant tumors
BCCA CODE: P1T986205
| April 2016 |
| A phase I trial of MK-3475 Plus Ziv-Aflibercept in patients with advanced solid tumours
BCCA CODE: P1PJC016 | August 2015 |
| A phase I/II study of MG1 MARABA/MAGE-A3 (MG1MA3), with and without adenovirus vaccine, with transgenic MAGE-A3 insertion (AdMA3) in patients with incurable advanced metastatic MAGE-A3 expressing solid tumours
BCCA CODE: P1IND214 | July 2015 |
| | A phase I trial of single agent trametinib (GSK1120212) in advanced cancer patients with dysfunction
BCCA CODE: P1PJC015 | June 2014 |
| | A phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of AZD5363 under adaptable dosing schedules in patients with advanced solid malignancies
BCCA CODE: P1TGIVEN | June 2014 |
| SARCOMA |
| |
SKIN - MELANOMA
| A phase III randomized, double-blind, placebo-controlled study comparing the combination of PDR001, daBRAFenib and trametinib versus placebo, daBRAFenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma
BCCA CODE: SMTCOMBII
| 15 May 2018
|
| A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP)
BCCA CODE: SMME13
| October 2016
|
SYMPTOM MANAGEMENT/
SUPPORTIVE CARE
| A randomized, double-blind, placebo controlled crossover trial of the use of Subcutaneous Lidocaine Infusion (SCLI) for chronic cancer-related pain
BCCA CODE: LIDOCAINE | January 2012 |
| Sennosides PEG study
A randomized, double-blind, double-dummy, 2 treament, 2 period, cross-over comparison of Sennosides and Polyethylene Glycol for constipation in outpatients with cancer
BCCA CODE: SCTPEGSEN | April 2010 |
MULTIPLE
SITES | Utilization of genomic information to augment chemotherapy decision-making for people with incurable malignancies
BCCA CODE: no BCCA code available | July 2012 |
